ArticleClinical ophthalmology (Auckland, N.Z.)2023
Canaloplasty and Trabeculotomy with the OMNI System in Patients with Open-Angle Glaucoma: Two-Year Results from the ROMEO Study.
Article in Clinical ophthalmology (Auckland, N.Z.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Systematic review and meta-analysis of the clinical effectiveness, safety, humanistic and economic burden of the OMNIEuropean journal of ophthalmology · 2026Pooled it
- Viscodilation of Schlemm canal and trabeculotomy for reducing intraocular pressure and medication use in pseudophakic eyes.Journal of cataract and refractive surgery · 2026Article
- Early success and safety of three minimally invasive glaucoma surgery techniques combined with cataract surgery in glaucoma patients.International ophthalmology · 2025Observational
- Ab Interno Goniotomy/Goniectomy TechniquesTurkish journal of ophthalmology · 2025Review
- Visual Function After Schlemm's Canal-Based MIGS.Journal of clinical medicine · 2025Review
- Two-Year Data on the Efficacy and Safety of the MINIject Supraciliary Implant in Patients with Medically Uncontrolled Primary Open-Angle Glaucoma.Journal of clinical medicine · 2025Article
- An Emerging Multi-mechanism and Multi-modal Approach in Interventional Glaucoma Therapy.Ophthalmology and therapy · 2025Article
- Standalone Canaloplasty and Trabeculotomy Using the OMNI Surgical System: A Subgroup Analysis from the American Academy of Ophthalmology IRISClinical ophthalmology (Auckland, N.Z.) · 2025Article
- Historical and Contemporary Debates in Schlemm's Canal-Based MIGS.Journal of clinical medicine · 2024Review
- Comparison of Superior versus Inferior Canaloplasty and Trabeculotomy Using the OMNI Surgical System.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Prospective Study of Canaloplasty and Trabeculotomy Performed by Trainees.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Alternatives to Topical Glaucoma Medication for Glaucoma Management.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- 36-Month Outcomes from the Prospective GEMINI Study: Canaloplasty and Trabeculotomy Combined with Cataract Surgery for Patients with Primary Open-Angle Glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- A Review of Canaloplasty in the Treatment and Management of Glaucoma.Journal of current glaucoma practiceReview
- Canaloplasty and Trabeculotomy Using the OMNI Surgical System in Three Patients with Angle Closure: A Case Series.Journal of current glaucoma practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To provide extended safety and effectiveness follow-up for eyes treated with circumferential canaloplasty and trabeculotomy (CP+TR) that were included in the 12-month ROMEO study. Setting: Seven multi-subspecialty ophthalmology practices located in 6 states (Arkansas, California, Kansas, Louisiana, Missouri, and New York). Design: Retrospective, multicenter, IRB approved. Subjects: Eligible eyes had mild-moderate glaucoma and were treated with CP+TR with cataract surgery or as a standalone intervention. Methods: Main outcome measures were mean IOP, mean number of ocular hypotensive medications, mean change in number of medications, proportion of patients with a ≥20% reduction in IOP or with IOP ≤18 mmHg, and proportion of patients medication free. Safety outcomes were adverse events and secondary surgical interventions (SSI). Results: Eight surgeons at 7 centers contributed 72 patients stratified by pre-operative intraocular pressure (IOP); >18 mmHg (Grp1), ≤18 mmHg (Grp2). Mean follow-up of 2.1 years (min 1.4, max 3.5). 2-year IOP (SD) was 15.6 mmHg (-6.1 mmHg, -28% from baseline) on 1.4 medications (-0.9, -39%) for Grp1 with cataract surgery; 14.7 mmHg (-7.4 mmHg, -33% from baseline) on 1.6 medications (-0.7, -15%) for Grp1 standalone, 13.7 mmHg (-0.6 mmHg, -4.2%) on 1.2 medications (-0.8, -35%) for Grp2 with cataract surgery, 13.3 mmHg (-2.3 mmHg, -14.7%) on 1.2 medications (-1.0, -46%) for Grp2 standalone. The proportion of patients at 2 years with either a ≥20% IOP reduction or IOP between 6 and 18 mmHg and no increase in medication or SSI was 75% (54 of 72, 95% CI 69.9%, 80.1%). One-third of patients (24 of 72) were medication free whereas 9 of 72 were pre-surgical. No device-related adverse events during extended follow-up; 6 eyes (8.3%) required additional surgical or laser intervention for IOP control after 12 months. Conclusion: CP+TR provides effective IOP control that is sustained for 2 years or more.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.